MARKET

RGNX

RGNX

Regenxbio
NASDAQ
7.23
-0.04
-0.48%
Opening 15:42 11/19 EST
OPEN
7.33
PREV CLOSE
7.26
HIGH
7.40
LOW
7.07
VOLUME
470.46K
TURNOVER
--
52 WEEK HIGH
16.19
52 WEEK LOW
5.46
MARKET CAP
477.74M
P/E (TTM)
-2.2501
1D
5D
1M
3M
1Y
5Y
1D
Stocks to Watch for Wednesday: TJX, TTWO, TGT & more
Seeking Alpha · 1d ago
Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick
Seeking Alpha · 1d ago
Weekly Report: what happened at RGNX last week (1109-1113)?
Weekly Report · 3d ago
REGENXBIO Earnings Call Signals Progress Toward Gene Therapy Launch
TipRanks · 4d ago
News Flash: Analysts Just Made A Notable Upgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) Forecasts
Simply Wall St · 11/11 10:24
Weekly Report: what happened at RGNX last week (1102-1106)?
Weekly Report · 11/09 09:34
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Pretty Bullish On The Stock After Recent Results
Simply Wall St · 11/08 13:16
Regenxbio: 2 Major Catalysts Could Change The Investment Case
Seeking Alpha · 11/06 18:19
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.